Evidence map›Paper›PMID 37188916›Full record

ArticleNature biotechnology2024

Deep learning models to predict the editing efficiencies and outcomes of diverse base editors.

Nahye Kim, Sungchul Choi, Sungjae Kim, Myungjae Song, Jung Hwa Seo, Seonwoo Min, Jinman Park, Sung-Rae Cho, Hyongbum Henry Kim

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Intravitreal adenine base editing of RS1 improves vision in a preclinical mouse model of retinoschisis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Nahye Kim *Department of Pharmacology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Sungchul Choi *Department of Pharmacology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Sungjae KimPrecision Medicine Institute, Macrogen, Seoul, Republic of Korea.
Myungjae SongDepartment of Pharmacology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jung Hwa SeoDepartment and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-8489-7972
Seonwoo MinLG AI Research, Seoul, Republic of Korea.
Jinman ParkDepartment of Pharmacology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Sung-Rae ChoGraduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0003-1429-2684
Hyongbum Henry KimDepartment of Pharmacology, Yonsei University College of Medicine, Seoul, Republic of Korea. hkim1@yuhs.ac.ORCID http://orcid.org/0000-0002-4693-738X
Yonsei University · KRLG (South Korea) · KRMacrogen (South Korea) · KRUniversity of California, San Francisco · US

Funding

Ministry of Health and Welfare (Ministry of Health, Welfare and Family Affairs) HI21C1314Ministry of Trade, Industry and Energy (Ministry of Trade, Industry and Energy, Korea) HN21C0917 (H.H.K.))National Research Foundation of Korea (NRF) 2018R1A5A2025079National Research Foundation of Korea (NRF) 2022M3A9E4017127National Research Foundation of Korea (NRF) 2022M3A9F3017506National Research Foundation of Korea (NRF) 2022R1A3B1078084National Research Foundation of Korea (NRF) 2022R1C1C2004229
6 · The paper itself

Abstract

Applications of base editing are frequently restricted by the requirement for a protospacer adjacent motif (PAM), and selecting the optimal base editor (BE) and single-guide RNA pair (sgRNA) for a given target can be difficult. To select for BEs and sgRNAs without extensive experimental work, we systematically compared the editing windows, outcomes and preferred motifs for seven BEs, including two cytosine BEs, two adenine BEs and three C•G to G•C BEs at thousands of target sequences. We also evaluated nine Cas9 variants that recognize different PAM sequences and developed a deep learning model, DeepCas9variants, for predicting which variants function most efficiently at sites with a given target sequence. We then develop a computational model, DeepBE, that predicts editing efficiencies and outcomes of 63 BEs that were generated by incorporating nine Cas9 variants as nickase domains into the seven BE variants. The predicted median efficiencies of BEs with DeepBE-based design were 2.9- to 20-fold higher than those of rationally designed SpCas9-containing BEs.

Indexed as

Alkanesulfonic AcidsCRISPR-Cas SystemsDeep LearningCRISPR-Associated Protein 9Gene EditingRNA, Guide, CRISPR-Cas SystemsAlkanesulfonic AcidsBESCRISPR-Associated Protein 9RNA, Guide, CRISPR-Cas Systems

Identifiers

PMID37188916
OpenAlexW4376610549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.